Laboratory findings
. | Standard-risk patients (n = 114) . | |
---|---|---|
. | Median . | Range . |
Hemoglobin, g/dL | 10.2 | 2.1-34 |
Peripheral WBC count, ×103/µL | 5.5 | 1.4-103.4 |
Peripheral platelet count, ×103/µL | 40.5 | 3-339 |
Peripheral blasts, % | 3 | 0-88.9 |
Bone marrow blast, % | 22 | 0-100 |
Cytogenetic findings (n = 110 patients) | N | % |
Normal (constitutional trisomy 21 only) | 19 | 17 |
Translocations and inversions recurrent in de novo AML | 0 | 0 |
1q gain | 12 | 11 |
3q loss | 6 | 5 |
5p loss | 5 | 5 |
Monosomy 5 | 1 | 1 |
7p loss | 14 | 13 |
Monosomy 7 | 7 | 6 |
+8 | 33 | 30 |
+11 or 11q gain | 8 | 7 |
13q loss | 5 | 5 |
+14 | 8 | 7 |
+21 | 18 | 16 |
Complex karyotype | 13 | 12 |
. | Standard-risk patients (n = 114) . | |
---|---|---|
. | Median . | Range . |
Hemoglobin, g/dL | 10.2 | 2.1-34 |
Peripheral WBC count, ×103/µL | 5.5 | 1.4-103.4 |
Peripheral platelet count, ×103/µL | 40.5 | 3-339 |
Peripheral blasts, % | 3 | 0-88.9 |
Bone marrow blast, % | 22 | 0-100 |
Cytogenetic findings (n = 110 patients) | N | % |
Normal (constitutional trisomy 21 only) | 19 | 17 |
Translocations and inversions recurrent in de novo AML | 0 | 0 |
1q gain | 12 | 11 |
3q loss | 6 | 5 |
5p loss | 5 | 5 |
Monosomy 5 | 1 | 1 |
7p loss | 14 | 13 |
Monosomy 7 | 7 | 6 |
+8 | 33 | 30 |
+11 or 11q gain | 8 | 7 |
13q loss | 5 | 5 |
+14 | 8 | 7 |
+21 | 18 | 16 |
Complex karyotype | 13 | 12 |